Table 1 Patient characteristics.

From: Outcomes of elderly patients with relapsed refractory multiple myeloma (RRMM) treated with teclistamab: a multicenter study from the U.S. Multiple Myeloma Immunotherapy Consortium

Measure

Age group

p-value

≥75 (N = 83)

<75 (N = 302)

Age, median (range)

78 (75–92)

65 (31–74)

 

Gender, n (%)

  

0.35

 Male

40 (48%)

163 (54%)

 

 Female

43 (52%)

139 (46%)

 

Race, n (%)

  

0.0086

 White

65 (78%)

190 (63%)

 

 Non-White

18 (22%)

112 (37%)

 

ECOG ≥ 2a, n (%)

  

0.37

 Yes

23 (29%)

65 (24%)

 

 No

57 (71%)

208 (76%)

 

 NA

3

29

 

MajesTEC-1 eligible, n (%)

  

0.20

 Yes

22 (27%)

61 (20%)

 

 No

61 (73%)

241 (80%)

 

Baseline CrCl < 30 ml/min, n (%)

  

0.59

 Yes

11 (14%)

34 (11%)

 

 No

70 (86%)

265 (89%)

 

 NA

2

3

 

Baseline LDH > ULN, n (%)

  

0.58

 Yes

34 (43%)

120 (46%)

 

 No

46 (58%)

141 (54%)

 

 NA

3

41

 

Cytogenetic risk, n (%)

  

0.0301

 Highb

37 (45%)

175 (58%)

 

 Standard

46 (55%)

127 (42%)

 

Ultra high-risk myelomac, n (%)

  

0.0233

 Yes

10 (12%)

71 (24%)

 

 No

73 (88%)

231 (77%)

 

Bone marrow PC > 50%, n (%)

  

0.23

 Yes

5 (21%)

43 (36%)

 

 No

19 (79%)

78 (64%)

 

 NA

59

181

 

EMD at baseline, n (%)

  

0.0018

 Yes

18 (22%)

121 (40%)

 

 No

65 (78%)

181 (60%)

 

Prior lines of therapy ≥ 6, n (%)

  

0.22

 Yes

43 (52%)

175 (59%)

 

 No

40 (48%)

127 (42%)

 

Triple-class refractoryd, n (%)

  

0.06

 Yes

63 (77%)

257 (85%)

 

 No

20 (24%)

45 (15%)

 

Penta-class refractorye, n (%)

  

0.15

 Yes

24 (30%)

118 (39%)

 

 No

59 (71%)

184 (61%)

 

Prior autologous transplant, n (%)

  

<0.0001

 Yes

35(43%)

218 (72%)

 

 No

47 (57%)

84 (28%)

 

Prior anti-BCMA agent, n (%)

  

0.0003

 Yes

27 (33%)

166 (55%)

 

 No

56 (68%)

136 (45%)

 

Prior anti-GPRC5D agent, n (%)

  

1.00

 Yes

2 (2.4%)

9 (3%)

 

 No

81 (98%)

293 (97%)

 
  1. BCMA B-cell maturation antigen, CrCl Creatinine clearance, ECOG Eastern Cooperative Oncology Group, EMD extramedullary disease, GPRC5D G protein-coupled receptor class C group 5 member D, LDH lactate dehydrogenase, NA not available, PC plasma cells, ULN upper limit of normal.
  2. aAt the start of teclistamab.
  3. bDefined as del(17p), t(4;14), t(14;16) and/or gain or amplification of 1q21.
  4. cDefined as having ≥2 high-risk cytogenetic abnormalities.
  5. dDefined as being refractory to a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody.
  6. eDefined as being refractory to lenalidomide, pomalidomide, bortezomib, carfilzomib, and an anti-CD38 monoclonal antibody.
Back to article page